SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A.
(Euronext Paris: COX) today announced its financial results for 2007 and
provided an overview of its activities during the year. NicOx also
announced today the initiation of two large Ambulatory Blood Pressure
Monitoring (ABPM) studies for naproxcinod (see separate press release).
Key highlights 2007:
-- Initiation of the two remaining pivotal phase 3 trials for naproxcinod
(the 302 and 303 studies) and completion of enrollment in the 302 study
-- Presentation of the naproxcinod phase 3 results at the American College
of Rheumatology (the 301 study) and data from an Ambulatory Blood
Pressure Monitoring trial at the American Heart Association (the 104
-- Initiation of a phase 2 proof-of-concept study designed to compare the
safety and efficacy of PF-03187207 to Pfizer Inc's Xalatan
-- Start of clinical development for the first nitric oxide-donating
antihypertensive by Merck & Co., Inc.
-- Initiation of a phase 2 proof-of-concept study for TPI 1020 in Chronic
Obstructive Pulmonary Disease (COPD), following promising top-line
results in a phase 2a study in asthmatic smokers
-- Establishment of NicOx' United States (U.S.) headquarters in Warren,
New Jersey, as a base for Commercial Affairs and Clinical Operations in
-- Strengthening of the Company's executive management team, through the
appointment of Pascal Pfister, MD as Chief Scientific Officer (CSO),
and Sanjiv Sharma as Vice President Commercial Affairs
"We envision that 2008 will be a transformational year for NicOx. We
expect to complete the pivotal phase 3 program for naproxcinod, including a
pooled analysis of the Office Blood Pressure Measurements, ahead of a
projected New Drug Application filing in mid-2009," said Michele Garufi,
|SOURCE NicOx S.A.|
Copyright©2008 PR Newswire.
All rights reserved